Latest:
Dr Freeman on Factors Influencing Response to CAR T-Cell Therapy in Hematology
Ciara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.
Authors
Kimberly Perez, MD
Kimberly Perez, MD is the Co-Director, Clinical Research, Division of Gastrointestinal Oncology, and an Assistant Professor of Medicine at Harvard Medical School.
Latest:
Dr Perez on the FDA Approval of Belzutifan for Advanced Pheochromocytoma and Paraganglioma
Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
Joern-Peter Halle, Global Head of Research at Merck KGaA, Darmstadt, Germany*
Latest:
Discovering New Medicines in Cancer
Our ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.
Catherine C. Coombs, MD
Catherine C. Coombs, MD, is a hematologist-oncologist and associate clinical professor in the Department of Medicine of the Division of Hematology/Oncology at University of California Irvine Health.
Latest:
Emerging Developments for the Treatment of R/R CLL
Panelists discuss how emerging therapies including BTK degraders, bispecific antibodies, and novel BCL-2 inhibitors represent exciting future treatment options for managing CLL patients across different lines of therapy.
Samantha A. Armstrong, MD
Samantha A. Armstrong, MD, is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health
Latest:
ASCO 2025 Plenary — MATTERHORN
Drs Armstrong and Tawagi discussed key data from the phase 3 MATTERHORN trial, which were presented at the 2025 ASCO Annual Meeting.
Fay Kastrinos, MD, MPH
Latest:
Understanding Lynch Syndrome and Associated Cancer Risk: Future Preventive Considerations
In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.
Meghan K. Berkenstock, MD
Latest:
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.
Gary Doherty, MRCP, PhD, Cambridge University Hospitals NHS Foundation Trust
Latest:
EGFR+ NSCLC: Advice for Community Oncologists
A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Jaume Capdevila, MD, PhD
Latest:
Efficacy and Safety of the DLL3/CD3 T-Cell Engager Obrixtamig in Patients With Extrapulmonary Neuroendocrine Carcinomas With High or Low DLL3 Expression: Results From an Ongoing Phase 1 Trial
Jaume Capdevila, MD, PhD, presents results from a phase 1 study showing that obrixtamig monotherapy achieves a 40% response rate and durable disease control with manageable safety in patients with extrapulmonary neuroendocrine carcinoma, particularly those with high DLL3 expression.